Metabolic enzyme promotes neuroblastoma aggressiveness
(Boston University School of Medicine) High-risk neuroblastoma is an aggressive childhood cancer with poor treatment outcomes. Despite intensive chemotherapy and radiotherapy, less than 50 percent of these children survive for five years. While the genetics of human neuroblastoma have been extensively studied, actionable therapeutics are limited. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news

Researchers on a mission to fight deadly childhood cancer
(University of South Australia) Neuroblastoma is the deadliest and most common solid cancer in young children the world over, accounting for 15 per cent of all childhood cancer deaths. But Australian researchers are taking the first steps to find the cause and better treatments for this devastating disease which affects children under the age of five. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2021 Category: Cancer & Oncology Source Type: news

Nerve tumor in children: better tolerable chemotherapy without loss of efficacy
(St. Anna Children's Cancer Research Institute) The initial chemotherapy of aggressive childhood nerve tumors, so-called high-risk neuroblastomas, is crucial for ultimate survival. It has now been shown that the chemotherapy regimen used by the European Neuroblastoma Study Group is equally efficacious but better tolerated than a highly effective regimen from the US. This was the conclusion of an international trial coordinated by St. Anna Children's Cancer Research Institute. The study was published in the prestigious Journal of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news

' Remarkable' Results for Targeted Therapy of Rare CNS Tumors'Remarkable' Results for Targeted Therapy of Rare CNS Tumors
The results come from three small studies of targeted therapy for papillary craniopharyngiomas (PCPs), gliomas and neuroblastomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Study identifies risk for some childhood cancer patients developing secondary leukaemia
(Wellcome Trust Sanger Institute) New study used whole genome sequencing to gain further understanding of why some children develop secondary leukaemia after neuroblastoma treatment. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 28, 2021 Category: Biology Source Type: news

Multimodal therapy may hold key to treating aggressive childhood cancer
(Children's Cancer Institute Australia) Scientists at Children's Cancer Institute found combination of therapies appears to be effective against high-risk neuroblastoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 16, 2021 Category: International Medicine & Public Health Source Type: news

Possible origin of neuroblastoma in the adrenal glands discovered
(Medical University of Vienna) Since the tumour cells of neuroblastoma resemble certain cells in the adrenal glands, a joint research group investigated the cellular origin of these cells and sympathetic neurons during the embryonic development of human adrenal glands. They discovered a previously unknown cell type that might potentially be the origin of the tumour cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2021 Category: International Medicine & Public Health Source Type: news

Novel cancer vaccine targets oncogenes known to evade immunity in melanoma and neuroblastoma models
(Children's National Hospital) A personalized tumor cell vaccine strategy targeting Myc oncogenes combined with checkpoint therapy creates an effective immune response that bypasses antigen selection and immune privilege, according to a pre-clinical study for neuroblastoma and melanoma. The neuroblastoma model showed a 75% cure with long-term survival, researchers at Children's National Hospital found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 2, 2021 Category: International Medicine & Public Health Source Type: news

Bespoke neuroblastoma therapy weaponizes cell metabolism
(Virginia Commonwealth University) Preclinical research from VCU Massey Cancer Center published recently in the Proceedings of the National Academy of Sciences shows that the combination of two existing drugs can exploit the metabolic " hunger " of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2021 Category: International Medicine & Public Health Source Type: news

World-first discovery paves way to new cancer treatment
(Children's Cancer Institute Australia) Australian researchers have discovered a new way to target, neuroblastoma. The discovery may also have important implications for other child and adult (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2021 Category: Cancer & Oncology Source Type: news

Natural 'brake' against malignant neuroblastoma
(St. Anna Children's Cancer Research Institute) A factor that turns malignant tumors into benign ones? - That is exactly what scientists at St. Anna Children's Cancer Research Institute and colleagues have discovered. They studied tumors of the peripheral nervous system in children, namely neuroblastomas. The scientists discovered that the uncontrolled growth of benign neuroblastomas is stopped by a signal molecule produced by Schwann cells present within these tumors. This natural " brake " also works on malignant neuroblastoma cultures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2021 Category: Cancer & Oncology Source Type: news

Natural " brake " against malignant neuroblastoma
(St. Anna Children's Cancer Research Institute) A factor that turns malignant tumors into benign ones? - That is exactly what scientists at St. Anna Children's Cancer Research Institute and colleagues have discovered. They studied tumors of the peripheral nervous system in children, namely neuroblastomas. The scientists discovered that the uncontrolled growth of benign neuroblastomas is stopped by a signal molecule produced by Schwann cells present within these tumors. This natural " brake " also works on malignant neuroblastoma cultures. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2021 Category: Cancer & Oncology Source Type: news

Abundance of iron drives cell death and could inform novel treatments for neuroblastoma
(Virginia Commonwealth University) Anthony Faber, Ph.D., and a team of researchers at VCU Massey Cancer Center were awarded a grant from the American Cancer Society to study how the gene MYCN and an abundance of iron can drive cancer cell death in neuroblastoma and potentially be targeted with novel treatments. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2021 Category: Cancer & Oncology Source Type: news

Researchers identify gene implicated in neuroblastoma, a childhood cancer
(Mayo Clinic) A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2021 Category: Cancer & Oncology Source Type: news

Researchers identify gene implicated in neuroblastoma, a childhood cancer
ROCHESTER, Minn. ? A new study by Mayo Clinic researchers has identified that a chromosome instability gene,?USP24,?is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - February 15, 2021 Category: Research Source Type: news

Stirring up conflicts in tumour cells
(University of W ü rzburg) With two commercially available inhibitors, the cell cycle of the cancer cells in the childhood tumour neuroblastoma can be disrupted at a key point causing tumour cell death. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news

New drug targets for childhood cancer neuroblastoma identified
(Wellcome Trust Sanger Institute) The largest single cell study to date of the childhood cancer, neuroblastoma, has discovered that all neuroblastomas arise from a single type of embryonic cell called sympathoblasts. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news

How Do You Know if Your Child Has Neuroblastoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 27, 2021 Category: General Medicine Source Type: news

Creating a safe CAR T-Cell therapy to fight solid tumors in children
(Children's Hospital Los Angeles) Scientists modify CAR T-Cell therapy, making it more effective and less toxic, for possible use in solid tumors such as neuroblastoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Drug combination increases susceptibility to chemotherapy in cases of severe neuroblastoma
(University of Gothenburg) Researchers at the University of Gothenburg now suggest a possible cure for children with hard-to-treat forms of neuroblastoma using a new combination of drugs. In a new study in the journal Cancer Research, they describe how a two small molecule-based drug combination likely inhibit the tumor's growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 7, 2021 Category: Cancer & Oncology Source Type: news

VRK1: a protein that reduces the survival of patients with neuroblastoma
(University of Seville) Researchers have characterised the function of VRK1 in neuroblastoma tumour cells and have determined that this protein is essential for tumour cell growth and proliferation. " By studying the expression of this protein in tumours, we were able to identify a priori patients where tumour progression is going to be worse, even in groups where current tools do not predict that behaviour, " notes Francisco M. Vega. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

Reductive stress in neuroblastoma cells aggregates protein and impairs neurogenesis
(University of Alabama at Birmingham) Cells require a balance among oxidation-reduction reactions, or redox homeostasis. Loss of that balance to create oxidative stress is often associated with neurodegeneration. Less is known about how loss of that balance at the other end of the spectrum -- reductive stress -- may affect neurons. Now researchers show for the first time that reductive stress promotes protein aggregation in neuroblastoma cells and impairs neurogenesis. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 8, 2020 Category: Biology Source Type: news

Monthly News Roundup - November 2020
Danyelza Gains Accelerated Approval to Treat Neuroblastoma Neuroblastoma is a solid tumor of childhood that occurs in the nervous system outside of the brain. Some tumors are easily treatable, but the majority are aggressive in nature. In... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the“Company” or“Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 27, 2020 Category: Drugs & Pharmacology Source Type: news

New Drug Approved for Neuroblastoma Based on MSKCC Research New Drug Approved for Neuroblastoma Based on MSKCC Research
Naxitamab has been approved for pediatric and adult patients with relapsed/refractory neuroblastoma in the bone and bone marrow that has responded to prior therapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

New immunotherapy shows promise against rare childhood cancer
(University College London) A novel CAR T-cell therapy developed by researchers at UCL and designed to target cancerous tumours, has shown promising early results in children with neuroblastoma, a rare form of childhood cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 25, 2020 Category: International Medicine & Public Health Source Type: news

Early trial hints CAR T cells may combat solid tumors in children with neuroblastoma
(American Association for the Advancement of Science) A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2020 Category: Cancer & Oncology Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Researchers mine data and connect the dots about processes driving neuroblastoma
(St. Jude Children's Research Hospital) St. Jude Children's Research Hospital scientists lead genome analysis to better understand one of the most common childhood solid tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 14, 2020 Category: International Medicine & Public Health Source Type: news

Promising treatment for aggressive childhood cancer
(Lund University) A drug has shown great promise in the treatment of neuroblastoma, an aggressive form of childhood cancer. The study was led by researchers at Lund University in Sweden, and is published in the journal Science Translational Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 6, 2020 Category: Cancer & Oncology Source Type: news

MAX binding with the variant Rs72780850 in RNA helicase DDX1 for susceptibility to neuroblastoma
(Science China Press) The researchers adopted the functional polymorphism research strategy to screen out the functional polymorphisms associated with neuroblastoma in Chinese population and elucidate its mechanism, providing data on children susceptible to neuroblastoma in China. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 11, 2020 Category: Biology Source Type: news

FDA grants rare disease designation to Clarity agent
Radiopharmaceutical firm Clarity Pharmaceuticals announced that the U.S. Food...Read more on AuntMinnie.comRelated Reading: Clarity's breast imaging agent enters clinical trial Clarity begins trial for pediatric neuroblastoma therapy Clarity, ImaginAb team to develop theranostic agents NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 10, 2020 Category: Radiology Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Clarity's breast imaging agent enters clinical trial
Radiopharmaceutical firm Clarity Pharmaceuticals said that its copper-64 SAR-Bombesin...Read more on AuntMinnie.comRelated Reading: Clarity begins trial for pediatric neuroblastoma therapy Clarity, ImaginAb team to develop theranostic agents NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 29, 2020 Category: Radiology Source Type: news

Clarity begins trial for pediatric neuroblastoma therapy
Radiopharmaceutical firm Clarity Pharmaceuticals has begun recruitment for...Read more on AuntMinnie.comRelated Reading: Clarity, ImaginAb team to develop theranostic agents NorthStar inks supply deal with Clarity (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 23, 2020 Category: Radiology Source Type: news

Could the willow help us fight cancer?
An ingredient in its bark led to aspirin, now researchers are looking into the properties of another compound in the treeWillow trees are a pharmaceutical treasure trove. The ancient Egyptians used its bark for relieving pain, inflammation and fevers, and science has since shown these medical powers came from an ingredient called salicin, named aftersalix, the Latin name for the tree. That discovery eventually led to the manufacture of aspirin, one of the most widely used medicines in the world.Recently another potential drug has been found in willow, one with anti-cancer powers. Scientists atRothamsted Research in Hertfor...
Source: Guardian Unlimited Science - July 14, 2020 Category: Science Authors: Paul Simons Tags: Science Trees and forests Environment UK news Cancer research Medical research Source Type: news

T1 mapping shows promise for assessing neuroblastoma
The common MRI technique called T1 mapping -- typically used for patients with...Read more on AuntMinnie.comRelated Reading: Imaging shows new, post-SARS-CoV-2 illness in children Preop MRI finds 11% more cancer in women with DCIS PET, MRI uncover women's predisposition to Alzheimer's Imaging reveals baby girl in SC born with 2nd mouth Caution indicated with new GBCAs for kidney patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 1, 2020 Category: Radiology Source Type: news

New radioisotope works better for certain cancers
A new radiopharmaceutical has shown better imaging performance in tumor detection,...Read more on AuntMinnie.comRelated Reading: New radioisotope therapy treats pediatric neuroblastoma Groups ask NRC to allow virtual radiotracer training New tau PET tracer better targets source of Alzheimer's Navidea touts phase IIB study looking at RA New PET/CT tracer reliably detects prostate cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 29, 2020 Category: Radiology Source Type: news

New radioisotope therapy treats pediatric neuroblastoma
Japanese researchers have discovered a new radioisotope therapy for children...Read more on AuntMinnie.comRelated Reading: Researchers link brain tumor treatment to GBCA deposition AJR paper describes errors in pediatric radiography Whole-body MRI has mixed results in pediatric cancer patients Dell donates cloud cluster for pediatric cancer trial Protocols protect pediatric caregivers from I-131 exposure (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 22, 2020 Category: Radiology Source Type: news

A novel radioisotope therapy for children with neuroblastoma
(Kanazawa University) Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose131I-metaiodobenzylguanidine at Kanazawa University Hospital. They showed that within a 5-year period, this therapy could provide a favorable prognosis without severe non-hematological side effects. These findings could provide new insights into a novel treatment option for patients with high-risk neuroblastoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 19, 2020 Category: Cancer & Oncology Source Type: news

Neuroblastoma: Overview Video Neuroblastoma: Overview Video
This video covers key aspects of neuroblastoma, including the causes, symptoms, diagnosis, and treatment.Osmosis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2020 Category: Consumer Health News Tags: Med Students Commentary Source Type: news

Rice University bioscientist Rosa Uribe wins NSF CAREER Award
(Rice University) Rice University neurodevelopmental biologist Rosa Uribe has won a prestigious CAREER Award from the National Science Foundation to study neural crest cells, specialist stem cells that form the enteric nervous system and also cause neuroblastoma, the third most prevalent form of pediatric cancer in the U.S. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 18, 2020 Category: Biology Source Type: news

Dynamic interactions of the 5-HT6 receptor with protein partners control dendritic tree morphogenesis
This study highlights the complex allosteric modulation of GPCRs by protein partners and demonstrates how dynamic interactions between GPCRs and their protein partners can control the different steps of highly coordinated cellular processes, such as dendritic tree morphogenesis. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - February 10, 2020 Category: Science Authors: Pujol, C. N., Dupuy, V., Seveno, M., Runtz, L., Bockaert, J., Marin, P., Chaumont-Dubel, S. Tags: STKE Research Articles Source Type: news

New method for monitoring residual disease after treatment in children with neuroblastoma
(Kobe University) Neuroblastoma is a cancer that affects children, characterized by solid tumors that develop from immature nerve cells. Over 50% of patients with high-risk neuroblastoma experience tumor relapse/regrowth.A research group led by Professor NISHIMURA Noriyuki (Graduate School of Health Sciences, Kobe University) has developed a new method to monitor the residual disease after treatment in high-risk neuroblastoma patients. The method could be utilized to evaluate treatment response and facilitate early diagnosis of tumor relapse/regrowth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 6, 2020 Category: Cancer & Oncology Source Type: news

Boy, six, visited his GP 11 TIMES before diagnosis of the 'largest tumour medics had ever seen'
Ellis Edwards, from Bournemouth, has stage four aggressive neuroblastoma. It was missed on successive trips to the doctors when his parents worried about his weight loss. (Source: the Mail online | Health)
Source: the Mail online | Health - February 4, 2020 Category: Consumer Health News Source Type: news

Smart algorithm finds possible future treatment for childhood cancer
(Uppsala University) Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma. This form of cancer in children, which occurs in specialised nerve cells in the sympathetic nervous system, may be life-threatening. In the long term the discovery, described in the latest issue of the scientific journal Nature Communications, may result in a new form of treatment for children in whom the disease is severe or at an advanced stage. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 7, 2020 Category: Cancer & Oncology Source Type: news

Research sheds important light on the metastasis of neuroblastoma
(Children's Cancer Institute Australia) Research sheds important light on the metastasis of neuroblastoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2019 Category: Cancer & Oncology Source Type: news